Want to see SG:T14 full AI Analyst Report?
Top Page
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S
(SGX:T14)
Select Model
Select Model
Rating:65Neutral
Price Target:
$2.50
â–¼(-23.31% Downside)
Action:Downgraded
Date:08/20/26
The score is supported primarily by strong financial resilience (very low leverage and solid cash flow), but is held back by weakening revenue/earnings trends and clearly bearish technical indicators (price below major moving averages with negative MACD). A high dividend yield helps, but the higher P/E limits the valuation boost.
Positive Factors
Very Low Leverage
Extremely low debt reduces refinancing and solvency risk, preserving capacity to fund operations, product development and distributions through weaker cycles. Solid equity and positive returns add resilience without dependence on leverage.
Negative Factors
Revenue Contraction
TTM revenue is contracting, while the broader revenue-growth measure is negative. Persistent top-line pressure would constrain operating leverage, distribution scale and the funds available for product investment.
Read all positive and negative factors
Positive Factors
Negative Factors
Very Low Leverage
Extremely low debt reduces refinancing and solvency risk, preserving capacity to fund operations, product development and distributions through weaker cycles. Solid equity and positive returns add resilience without dependence on leverage.
Read all positive factors
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (T14) vs. iShares MSCI Singapore ETF (EWS)
Market Cap
$3.50B
Dividend Yield13.69%
Average Volume (3M)117.62K
Price to Earnings (P/E)32.1
Beta (1Y)0.16
Revenue Growth-18.50%
EPS Growth-74.83%
CountrySG
Employees3,890
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.10
Shares Outstanding200,000,000
10 Day Avg. Volume127,120
30 Day Avg. Volume117,623
Financial Highlights & Ratios
PEG Ratio-1.92
Price to Book (P/B)2.58
Price to Sales (P/S)3.73
P/FCF Ratio53.57
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.2
Revenue Forecast (FY)$750.82M
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S Business Overview & Revenue Model
Company Description
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (TPDRTG), a prominent pharmaceutical group operating with its various subsidiaries, primarily serves the People's Republic of China. Its core focus lies in the production and sale of tra...
How the Company Makes Money
null...
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
90
Very Positive
Cash Flow
68
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.71B | 4.92B | 7.31B | 8.22B | 8.25B | 6.91B |
| Gross Profit | 3.51B | 3.64B | 3.52B | 3.62B | 3.29B | 2.76B |
| EBITDA | 996.69M | 2.61B | 2.74B | 1.26B | 1.11B | 991.28M |
| Net Income | 847.52M | 2.13B | 2.23B | 986.71M | 861.79M | 769.14M |
Balance Sheet | ||||||
| Total Assets | 10.54B | 11.69B | 10.77B | 10.23B | 10.16B | 9.07B |
| Cash, Cash Equivalents and Short-Term Investments | 3.53B | 1.02B | 3.94B | 2.15B | 2.88B | 2.28B |
| Total Debt | 98.38M | 62.56M | 27.26M | 325.58M | 257.91M | 33.17M |
| Total Liabilities | 4.52B | 4.59B | 2.92B | 3.58B | 3.61B | 2.55B |
| Stockholders Equity | 5.94B | 7.10B | 7.84B | 6.60B | 6.52B | 6.36B |
Cash Flow | ||||||
| Free Cash Flow | 777.35M | 342.45M | 806.86M | 547.56M | 569.34M | 695.45M |
| Operating Cash Flow | 890.12M | 461.07M | 924.67M | 688.49M | 677.25M | 852.40M |
| Investing Cash Flow | 831.74M | -1.41B | 342.31M | -744.21M | -12.28M | -311.85M |
| Financing Cash Flow | -2.89B | -980.88M | -319.89M | -836.65M | -236.62M | -244.70M |
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S Peers Comparison
UnderperformOutperform
Sector (55)
SG:T14
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S
2.56
0.24
10.15%
SG:1J5
Hyphens Pharma International Ltd.
0.37
0.06
19.28%
SG:42C
iX Biopharma Ltd.
0.46
0.44
2175.00%
SG:546
Medtecs International Corporation Ltd.
0.11
-0.01
-9.60%
SG:8YY
Biolidics Ltd.
0.03
<0.01
34.78%
SG:BFK
Pharmesis International Ltd.
0.13
-0.30
-70.31%
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S Corporate Events
Tianjin Da Ren Tang Board Clears FY2026 Half-Year Reports and Governance Changes
Aug 14, 2026
The board of Tianjin Pharmaceutical Da Ren Tang Group convened its seventh meeting for FY2026 on 13 August 2026, confirming compliance with PRC Company Law, Securities Law and the firm’s Articles of Association. Directors approved the compan...
Tianjin Da Ren Tang Redirects Placement Proceeds to Working Capital After Project Cessations
Aug 14, 2026
Tianjin Pharmaceutical Da Ren Tang Group reported on the status of net proceeds from its 2015 A-share placement, confirming strict compliance with Chinese regulatory requirements for the deposit and use of funds. As at 30 June 2026, the company ha...
Tianjin Pharmaceutical Da Ren Tang Updates Risk Review of Group Finance Unit
Aug 14, 2026
Tianjin Pharmaceutical Da Ren Tang Group has released its latest semi-annual continuous risk assessment report on Tianjin Pharmaceutical Group Finance Co., Ltd., a related finance company within the Tianjin Pharmaceutical Holdings group. The discl...
Tianjin Da Ren Tang Proposes Governance-Focused Amendments to Articles of Association
Aug 14, 2026
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has proposed amendments to its Articles of Association to align its corporate governance with the revised PRC Company Law and the China Securities Regulatory Commission’s 2025 guid...
Tianjin Da Ren Tang Wins Approval for New Sustained-Release Diabetes Drug
Aug 7, 2026
Xinxin Pharmaceutical Plant, a branch of Tianjin Pharmaceutical Da Ren Tang Group, has obtained a Drug Registration Certificate from China’s National Medical Products Administration for Saxagliptin and Metformin Hydrochloride Sustained-relea...
Tianjin Pharmaceutical Da Ren Tang Board Clears Key Related-Party Distribution and Logistics Deals
Aug 7, 2026
The board of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited convened its sixth meeting for the 2026 financial year on 7 August 2026, combining a physical session with teleconference in compliance with Chinese corporate and securities...
Tianjin Da Ren Tang Sets RMB113m Distribution Deal With Related Pharma Affiliates
Aug 7, 2026
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited plans to enter an annual distribution agreement via its Health Technology Industry Development Branch with Tianjin Pharmaceutical Group Taiping Medicine and Tianjin Zhongxin Medicine, bo...
Tianjin Da Ren Tang Sets RMB19m Logistics Deal With Affiliate Taiping Medicine
Aug 7, 2026
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited plans to replace its expiring third-party warehousing contract by engaging Tianjin Pharmaceutical Group Taiping Medicine Co., Ltd. for warehousing and logistics services through its Heal...
Controlling Shareholder of Tianjin Pharmaceutical Da Ren Tang Slightly Raises Stake in S-Shares
Aug 4, 2026
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, previously known as Tianjin Zhong Xin Pharmaceutical Group, is a China-based pharmaceutical firm with both A-shares and S-shares, the latter traded on the Singapore Exchange. Its contro...
Tianjin Da Ren Tang Reports No New Impact From Subsidiary Bankruptcy
Jul 31, 2026
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, formerly Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, is a China-based pharmaceutical group operating through multiple subsidiaries. The company is subject to listing rul...
Tianjin Da Ren Tang Sees Headline Profit Slump, Core Earnings Edge Higher in 1H 2026
Jul 14, 2026
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has issued an earnings estimate for the six months ended June 30, 2026, projecting net profit attributable to equity holders at RMB620 million to RMB660 million. This headline figure rep...
Tianjin Da Ren Tang Reports No New Impact From Subsidiary Bankruptcy
Jun 30, 2026
The board of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has issued its latest monthly update on the bankruptcy liquidation of Tianjin Shin Poong Pharmaceutical Co., Ltd., a 55%-owned subsidiary in China. The company reports that ...
Tianjin Da Ren Tang Refines Board Committees and Overhauls 2026 Pay Framework
Jun 25, 2026
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has reshuffled its board committees following the retirement of independent director Liew Yoke Pheng Joseph and the appointment of new independent director Zhai Shuping. Zhai now chairs ...
Tianjin Da Ren Tang Shareholders Back All FY2025 AGM Resolutions
Jun 3, 2026
Shareholders of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited approved all resolutions at the annual general meeting for the year ended 31 December 2025, held in Tianjin with concurrent video participation in Singapore. The meeting ...
Tianjin Da Ren Tang Reports No New Impact From Subsidiary Bankruptcy Proceedings
Jun 2, 2026
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has provided its latest monthly update on the bankruptcy liquidation of Tianjin Shin Poong Pharmaceutical Co., Ltd., a 55%-owned subsidiary in China. The board reiterated its responsibil...
Tianjin Da Ren Tang Schedules Online Briefing on FY2025 and Q1 2026 Results
Jun 2, 2026
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited will host an online investor conference on 10 June 2026 to discuss its full-year 2025 financial results and unaudited results for the three months ended 31 March 2026. The session, held ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.